Clinical Trials - August 21, 2020
First patient dosed in Vaccibody and Nektar Therapeutic trial
The first patient has been dosed in the combination therapy of the Phase 1/2a study evaluating Nektar’s CD122-preferential IL-2 pathway agonist with Vaccibody’s personalized neoantigen cancer vaccine, in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). “We’re pleased to advance our collaboration with Vaccibody to evaluate the potential of bempeg given […]
Drug Development Pharma - November 19, 2013
Naloxegol reaches milestone
AstraZeneca has announced that the United States Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for naloxegol. The investigational peripherally-acting mu-opioid receptor antagonist (PAMORA) has been studied in opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, the most common side effect caused by chronic administration of prescription opioid pain […]